sean mcdonald
ocugenix inc.
president & Chief Executive Officer
Mr. McDonald is a seasoned healthcare and technology executive who has built multiple companies from startup to more than $100 million in revenue. He’s had success in both the startup and Fortune 50 settings. Mr. McDonald is experienced in building technical, scientific, service, sales and clinical organizations. He raised more than $200 million in venture capital investment over multiple companies in various industries.
As co-founder and president/chief executive officer of Ocugenix, Mr. McDonald has led the founding and development of a therapeutic company focused on developing therapies related to angiopathies of the eye. The initial targeted indications include wet macular degeneration and diabetic retinopathy diseases, which take the sight of tens of millions of people throughout the world. Mr. McDonald has been responsible for initial licensing, clinical strategy development, initial fund raise and scientific development. The company is in the IND process and hopes to commence clinical development in humans in late 2019.
As president and chief executive officer, Mr. McDonald built Precision Therapeutics into a market-leading personalized medicine company through internal development as well as executing an aggressive acquisition strategy. He drove overall business strategy (including product development, clinical validation and market development), and achieved proprietary reimbursement for products, realizing gross margins in excess of 85 percent. Mr. McDonald developed the most diversified portfolio in the industry of validated personalized medicine products impacting lung, colon and gynecological cancers.
As group president of McKesson, Mr. McDonald oversaw six separate operating divisions delivering technology solutions as diverse as robotics, ERP systems and e-commerce systems. He turned around a shrinking technology division to a 30percent annual growth rate in the first year after assuming control.
Mr. McDonald also founded Automated Healthcare, a robotics-based automation system that transformed the pharmacy segment. The company was later sold to McKesson, realizing more than 600 percent ROI for investors.